Alector (ALEC) Competitors $1.86 +0.08 (+4.49%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALEC vs. IMNM, KURA, KROS, TYRA, CRON, ERAS, EOLS, DNTH, RAPP, and AUTLShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Cronos Group (CRON), Erasca (ERAS), Evolus (EOLS), Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Alector vs. Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Cronos Group Erasca Evolus Dianthus Therapeutics Rapport Therapeutics Autolus Therapeutics Alector (NASDAQ:ALEC) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations. Does the media favor ALEC or IMNM? In the previous week, Alector had 8 more articles in the media than Immunome. MarketBeat recorded 11 mentions for Alector and 3 mentions for Immunome. Immunome's average media sentiment score of 1.57 beat Alector's score of -0.37 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, ALEC or IMNM? Alector has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Do insiders & institutionals believe in ALEC or IMNM? 85.8% of Alector shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 9.1% of Alector shares are held by insiders. Comparatively, 8.6% of Immunome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ALEC or IMNM more profitable? Alector has a net margin of -257.54% compared to Immunome's net margin of -3,014.59%. Immunome's return on equity of -48.63% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-257.54% -108.77% -27.03% Immunome -3,014.59%-48.63%-41.62% Which has better valuation and earnings, ALEC or IMNM? Immunome has lower revenue, but higher earnings than Alector. Immunome is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$61.51M2.96-$130.39M-$1.70-1.09Immunome$10.13M67.60-$106.81M-$8.11-1.35 Do analysts prefer ALEC or IMNM? Alector currently has a consensus target price of $3.75, indicating a potential upside of 101.61%. Immunome has a consensus target price of $28.83, indicating a potential upside of 162.84%. Given Immunome's stronger consensus rating and higher probable upside, analysts clearly believe Immunome is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ALEC or IMNM? Alector received 124 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 61.02% of users gave Alector an outperform vote. CompanyUnderperformOutperformAlectorOutperform Votes15561.02% Underperform Votes9938.98% ImmunomeOutperform Votes3173.81% Underperform Votes1126.19% SummaryAlector and Immunome tied by winning 9 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.16M$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E Ratio-1.0946.7389.5817.17Price / Sales2.96415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book1.323.894.774.78Net Income-$130.39M-$42.21M$120.15M$225.60M7 Day Performance-5.58%-2.15%-1.92%-1.23%1 Month Performance-50.53%4.20%11.47%3.36%1 Year Performance-76.72%18.39%30.54%16.60% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector4.2493 of 5 stars$1.86+4.5%$3.75+101.6%-76.4%$182.16M$61.51M-1.09270Analyst DowngradeHigh Trading VolumeIMNMImmunome2.561 of 5 stars$12.48-0.8%$28.83+131.0%+33.0%$778.96M$10.13M-1.5540Positive NewsKURAKura Oncology4.4841 of 5 stars$9.92+3.0%$29.38+196.1%-27.0%$771.38MN/A-4.08142KROSKeros Therapeutics3.2934 of 5 stars$18.73-0.5%$81.33+334.2%-49.6%$758.70M$651,000.00-3.61100Gap DownHigh Trading VolumeTYRATyra Biosciences2.0686 of 5 stars$14.92-0.1%$31.00+107.8%+2.0%$754.95MN/A-9.2820CRONCronos Group1.8534 of 5 stars$1.94+0.5%$3.00+54.6%+4.8%$741.62M$87.24M-15.19356News CoverageERASErasca2.0792 of 5 stars$2.59+1.2%$5.90+127.8%+35.8%$732.26MN/A-3.08126News CoveragePositive NewsEOLSEvolus3.8293 of 5 stars$11.50-0.1%$23.00+100.0%+12.5%$728.18M$202.09M-12.73170DNTHDianthus Therapeutics1.3389 of 5 stars$24.36+2.3%$46.43+90.6%+213.2%$721.06M$2.83M-9.5280Analyst ForecastNews CoverageRAPPRapport Therapeutics1.5264 of 5 stars$19.38+3.2%$35.00+80.6%N/A$708.92MN/A0.00N/AAUTLAutolus Therapeutics2.5543 of 5 stars$2.63+5.6%$10.40+295.4%-58.4%$699.82M$1.70M-2.06330 Related Companies and Tools Related Companies Immunome Alternatives Kura Oncology Alternatives Keros Therapeutics Alternatives Tyra Biosciences Alternatives Cronos Group Alternatives Erasca Alternatives Evolus Alternatives Dianthus Therapeutics Alternatives Rapport Therapeutics Alternatives Autolus Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALEC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALEC Stock Alerts